FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3204114911> ?p ?o ?g. }

• W3204114911 endingPage "790" @default.
• W3204114911 startingPage "781" @default.
• W3204114911 abstract "Direct oral anticoagulants (DOACs) are an alternative to low-molecular-weight heparin for treating cancer-associated VTE.Is rivaroxaban as efficient and safe as dalteparin to treat patients with cancer-associated VTE?In a randomized open-label noninferiority trial, patients with active cancer who had proximal DVT, pulmonary embolism (PE), or both were assigned randomly to therapeutic doses of rivaroxaban or dalteparin for 3 months. The primary outcome was the cumulative incidence of recurrent VTE, a composite of symptomatic or incidental DVT or PE, and worsening of pulmonary vascular or venous obstruction at 3 months.Of 158 randomized patients, 74 and 84 patients were assigned to receive rivaroxaban and dalteparin, respectively. Mean age was 69.4 years, and 115 patients (76.2%) had metastatic disease. The primary outcome occurred in 4 and 6 patients in the rivaroxaban and dalteparin groups, respectively (both the intention-to-treat and per-protocol populations: cumulative incidence, 6.4% vs 10.1%; subdistribution hazard ratio [SHR], 0.75; 95% CI, 0.21-2.66). Major bleeding occurred in 1 and 3 patients in the rivaroxaban and dalteparin groups, respectively (cumulative incidence, 1.4% vs 3.7%; SHR, 0.36; 95% CI, 0.04-3.43). Major or clinically relevant nonmajor bleeding occurred in 9 and 8 patients in the rivaroxaban and dalteparin groups, respectively (cumulative incidence, 12.2% vs 9.8%; SHR, 1.27; 95% CI, 0.49-3.26). Overall, 19 patients (25.7%) and 20 patients (23.8%) died in the rivaroxaban and dalteparin groups, respectively (hazard ratio, 1.05; 95% CI, 0.56-1.97).In this trial comparing rivaroxaban and dalteparin in the treatment of cancer-associated VTE, the number of patients was insufficient to reach the predefined criteria for noninferiority, but efficacy and safety results were consistent with those previously reported with DOACs. An updated meta-analysis of randomized trials comparing DOACs with low-molecular-weight heparin in patients with cancer-associated VTE is provided.ClinicalTrials.gov; No.: NCT02746185; URL: www.gov." @default.
• W3204114911 created "2021-10-11" @default.
• W3204114911 creator A5004194543 @default.
• W3204114911 creator A5006010044 @default.
• W3204114911 creator A5010872053 @default.
• W3204114911 creator A5013736503 @default.
• W3204114911 creator A5020949450 @default.
• W3204114911 creator A5022673413 @default.
• W3204114911 creator A5023227285 @default.
• W3204114911 creator A5023797887 @default.
• W3204114911 creator A5023847182 @default.
• W3204114911 creator A5024688180 @default.
• W3204114911 creator A5025003700 @default.
• W3204114911 creator A5025879659 @default.
• W3204114911 creator A5026975565 @default.
• W3204114911 creator A5029783902 @default.
• W3204114911 creator A5030954104 @default.
• W3204114911 creator A5030985674 @default.
• W3204114911 creator A5032514115 @default.
• W3204114911 creator A5037496435 @default.
• W3204114911 creator A5037590032 @default.
• W3204114911 creator A5039781747 @default.
• W3204114911 creator A5040363397 @default.
• W3204114911 creator A5045010479 @default.
• W3204114911 creator A5045260727 @default.
• W3204114911 creator A5046625106 @default.
• W3204114911 creator A5046888718 @default.
• W3204114911 creator A5051922597 @default.
• W3204114911 creator A5051935323 @default.
• W3204114911 creator A5053233909 @default.
• W3204114911 creator A5053886056 @default.
• W3204114911 creator A5058354402 @default.
• W3204114911 creator A5058851349 @default.
• W3204114911 creator A5059786036 @default.
• W3204114911 creator A5061076514 @default.
• W3204114911 creator A5065252955 @default.
• W3204114911 creator A5068602437 @default.
• W3204114911 creator A5069153952 @default.
• W3204114911 creator A5070371776 @default.
• W3204114911 creator A5071211682 @default.
• W3204114911 creator A5073414182 @default.
• W3204114911 creator A5076037108 @default.
• W3204114911 creator A5086036714 @default.
• W3204114911 creator A5086499735 @default.
• W3204114911 creator A5086942347 @default.
• W3204114911 creator A5087559641 @default.
• W3204114911 creator A5087883382 @default.
• W3204114911 creator A5089021229 @default.
• W3204114911 creator A5089215000 @default.
• W3204114911 creator A5089460437 @default.
• W3204114911 creator A5091248099 @default.
• W3204114911 date "2022-03-01" @default.
• W3204114911 modified "2023-10-18" @default.
• W3204114911 title "Rivaroxaban vs Dalteparin in Cancer-Associated Thromboembolism" @default.
• W3204114911 cites W2041055738 @default.
• W3204114911 cites W2115787552 @default.
• W3204114911 cites W2118092611 @default.
• W3204114911 cites W2125435699 @default.
• W3204114911 cites W2130199362 @default.
• W3204114911 cites W2135936995 @default.
• W3204114911 cites W2162398328 @default.
• W3204114911 cites W2775434460 @default.
• W3204114911 cites W2802130786 @default.
• W3204114911 cites W2885394836 @default.
• W3204114911 cites W2954881683 @default.
• W3204114911 cites W2966354200 @default.
• W3204114911 cites W2970101385 @default.
• W3204114911 cites W2981274404 @default.
• W3204114911 cites W2989714602 @default.
• W3204114911 cites W3005192782 @default.
• W3204114911 cites W3013809005 @default.
• W3204114911 cites W3022434596 @default.
• W3204114911 cites W3127460195 @default.
• W3204114911 cites W3134171835 @default.
• W3204114911 cites W3155376029 @default.
• W3204114911 doi "https://doi.org/10.1016/j.chest.2021.09.037" @default.
• W3204114911 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34627853" @default.
• W3204114911 hasPublicationYear "2022" @default.
• W3204114911 type Work @default.
• W3204114911 sameAs 3204114911 @default.
• W3204114911 citedByCount "56" @default.
• W3204114911 countsByYear W32041149112021 @default.
• W3204114911 countsByYear W32041149112022 @default.
• W3204114911 countsByYear W32041149112023 @default.
• W3204114911 crossrefType "journal-article" @default.
• W3204114911 hasAuthorship W3204114911A5004194543 @default.
• W3204114911 hasAuthorship W3204114911A5006010044 @default.
• W3204114911 hasAuthorship W3204114911A5010872053 @default.
• W3204114911 hasAuthorship W3204114911A5013736503 @default.
• W3204114911 hasAuthorship W3204114911A5020949450 @default.
• W3204114911 hasAuthorship W3204114911A5022673413 @default.
• W3204114911 hasAuthorship W3204114911A5023227285 @default.
• W3204114911 hasAuthorship W3204114911A5023797887 @default.
• W3204114911 hasAuthorship W3204114911A5023847182 @default.
• W3204114911 hasAuthorship W3204114911A5024688180 @default.
• W3204114911 hasAuthorship W3204114911A5025003700 @default.
• W3204114911 hasAuthorship W3204114911A5025879659 @default.
• W3204114911 hasAuthorship W3204114911A5026975565 @default.

• next